It is now close to a decade since the first DOAC, dabigatran, was introduced to our shores for the prophylaxis and treatment of thrombotic disorders. This direct thrombin inhibitor (DTI) was later joined by two anti-Xa inhibitors, rivaroxaban and apixaban. DOACs have since drastically altered the anticoagulation landscape with expanded indications and wider acceptance by both clinicians and patients.
This lecture will discuss the progress of DOACs in the past decade in respect to its indications and safety and explore its future potential for both traditional and expanded indications as it continues to displace the classic anticoagulants in reducing thrombotic events.
Click here for more lecture details.